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Sir,
Colistin is among the very few antimicrobials that retain activity
against MDR Gram-negative bacteria. It binds to the negatively
charged LPS, leading to the disruption of the membrane.1 Since
its discovery, colistin has been used in veterinary medicine, in
particular in cattle and swine, usually collectively through prophy-
lactic or metaphylactic practices but also as individual treat-
ment.2,3 On the other hand, colistin is a last-resort antibiotic to
treat multiresistant bacteria in human medicine, although
colistin-resistant clinical isolates have recently been reported.
This raises concerns about the possibility that colistin-resistant
strains might be selected in animals and then might be the
sources of human infections.
Colistin resistance in Klebsiella pneumoniae is related to
modifications of LPS by addition of cationic charges, such as add-
ition of 4-amino-4-deoxy-L-arabinose to lipid A, which decreases
the affinity between colistin and its target.4 The modification of




PhoPQ and PmrAB two-component systems.5 It has been demon-
strated that MgrB, a small transmembrane protein, negatively
regulates the PhoPQ system by interaction with the sensor kinase
PhoQ in the periplasmic domain, preventing activation of the
pmrHFIJKLM operon.6
It was recently shown that insertional inactivation of the mgrB
gene in K. pneumoniae could result in up-regulation of the PhoPQ
system, leading to overexpression of the pmrHFIJKLM operon,
resulting in colistin resistance due to addition of positive charges
to lipid A.7,8 This was demonstrated in a KPC-producing isolate
from Italy and then among a series of clonally unrelated isolates
with worldwide origins. Interestingly, different genetic events
were identified at the origin of this resistance, being either the
insertion of different types of IS at different locations into the
mgrB gene or the occurrence of a premature stop codon in
the MgrB coding sequence. All these genetic events led to trunca-
tions of the mgrB gene and consequently impaired the production
of a functional MgrB protein.
The aim of this study was to evaluate the occurrence of colistin
resistance among K. pneumoniae isolates recovered from bovine
mastitis, a disease that can be treated by intra-mammary appli-
cation of colistin (mostly in combination with penicillins) in France,
and to decipher the corresponding mechanism(s). Ninety-seven
non-duplicate K. pneumoniae isolates that caused mastitis were
recovered through the Resapath network (www.resapath.anses.fr)
in 2013 and sent to Anses (Lyon) for further analysis.
Antimicrobial susceptibility testing was performed by broth
microdilution according to the EUCAST recommendations, using
cation-adjusted Mueller–Hinton broth.9 MICs of colistin were
determined by Etestw (bioMe´rieux, La Balme-les-Grottes, France)
and breakpoints were those recommended by the EUCAST:
.2 mg/L, resistant; and ≤2 mg/L, susceptible. Only 1 of the 97
isolates (isolate NK34373) showed resistance to colistin, with an
MIC of 8 mg/L. MLST, performed as previously described10 and
interpreted using the public MLST web site (http://bigsdb.web.
pasteur.fr/klebsiella/klebsiella.html), identified isolate NK34373
as being ST37. This isolate was susceptible to all other antibiotics
tested, including broad-spectrum cephalosporins, all amino-
glycosides, quinolones, fluoroquinolones, chloramphenicol and
tetracyclines.
A PCR specific for the mgrB gene was performed using primers
mgrB-Kp-F (5′-TTAAGAAGGCCGTGCTATCC-3′) and mgrB-Kp-R
(5′-AAGGCGTTCATTCTACCACC-3′). It revealed a larger amplicon
compared with a WTmgrB amplicon (data not shown) and sequen-
cing showed that the mgrB gene was interrupted by a 1057 bp
IS903B element (98% nucleotide identity) belonging to the IS5
family (https://www-is.biotoul.fr) (GenBank accession number
X02527). The IS was inserted into the mgrB gene between nucleo-
tides 67 and 68 and was bracketed by a 9 bp target site duplication
(5′-ACTCAGATG-3′), likely being the signature of a transposition
event. In parallel, sequence analysis of the pmrCAB operon as pre-
viously described11 identified WT genes.
Complementation experiments were then performed as previ-
ously described using recombinant plasmid pTOPO-mgrB or
pTOPO-pmrB, encoding WT K. pneumoniae MgrB and PmrB proteins,
respectively.10 Electro-transformation was performed by electropor-
ation into the colistin-resistant isolate NK34373 and electro-
transformants were selected onto Mueller-Hinton agar plates
supplemented with 100 mg/L zeocin (resistance marker of cloning
vectors). Complementation with plasmid pTOPO-mgrB fully restored
susceptibility to colistin, while the MIC of colistin remained
unchanged upon transformation with plasmid pTOPO-pmrB.
These results demonstrated that the loss of functional MgrB
was responsible for the colistin resistance trait observed in the
K. pneumoniae isolate. To the best of our knowledge, this is the
first description of a mechanism responsible for colistin resistance
in a veterinary strain. Notably, it corresponds to a mechanism that
is identical to that identified among human K. pneumoniae iso-
lates, i.e. the inactivation of the mgrB gene. As opposed to
those colistin-resistant isolates that have been identified among
human isolates, this isolate was susceptible to all other antibio-
tics. The routes of selection of colistin resistance in this isolate
remain unknown. It may result from local injection of colistin in
the infected udder, but colistin resistance might also have been
selected in the farm environment as a consequence of oral
administration of colistin to calves, then further eliminated in
the faeces. Owing to the wide use of colistin in veterinary medi-
cine, these results suggest that more extensive epidemiological
surveys should now be conducted to evaluate the prevalence
and molecular features of colistin-resistant isolates in animals.
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Sir,
Antimicrobial resistance in Neisseria gonorrhoeae is a major public
health concern globally. Over time, gonococci have developed
resistance to most antimicrobial agents used for first-line treat-
ment and declining susceptibility to the extended-spectrum
cephalosporins is emerging worldwide.1 – 3 Consequently, dual
antimicrobial therapy consisting of ceftriaxone (250 or 500 mg
by intramuscular injection) together with azithromycin (1 or 2 g orally)
is now recommended as standard treatment for gonorrhoea in the
USA, the UK and Europe and is now gradually being adopted in
major clinics throughout Australia.4 – 7 Monotherapy with 2 g of
azithromycin is an alternative treatment in patients who are aller-
gic to cephalosporins.4 These treatment regimens are threatened
by the emergence of azithromycin resistance in gonococci, particu-
larly high-level azithromycin resistance. High-level azithromycin
resistance in N. gonorrhoeae, defined by an azithromycin MIC
.256 mg/L, is associated with mutations in the peptidyltransfer-
ase loop in domain V of the 23S rRNA gene, principally A2059G,
and a single base pair deletion (A) in the promoter region of the
mtrR gene.8,9 Isolates of gonococci displaying high-level azithromy-
cin resistance have been reported from the UK, Italy, Argentina, the
USA and Sweden.10 – 14 Here, we provide the first report of gono-
cocci in Australia with high-level azithromycin resistance.
The Australian Gonococcal Surveillance Programme (AGSP)
monitors gonococcal antimicrobial resistance to a wide range of
antimicrobials, which is achieved through the referral of gonococ-
cal isolates from clinical diagnostic laboratories to nominated
state or territory reference laboratories. These reference labora-
tories together form the National Neisseria Network (NNN) of
Australia, through which 3500 N. gonorrhoeae isolates are
tested for antimicrobial resistance annually. Since 2011, six iso-
lates of gonococci submitted to NNN laboratories were found to
exhibit high-level azithromycin resistance: one isolate from the
state of New South Wales, two isolates from the state of
Victoria and three isolates from the state of Queensland. Details
are summarized in Table 1.
Briefly, identification was confirmed as N. gonorrhoeae on the
basis of Gram stain, oxidase, superoxol and carbohydrate utiliza-
tion tests or MALDI Biotyperw (Bruker Daltonik, Bremen, Germany).
Breakpoint MICs were initially determined by agar plate dilution
using the method of the AGSP.15 Azithromycin MICs were con-
firmed by Etests (bioMe´rieux, Marcy-l’E´toile, France). In addition,
the 23S rRNA and mtrR genes of each isolate were
Table 1. Characteristics of the first strains of N. gonorrhoeae with high-level resistance to azithromycin from Australia
Isolate/state Year Gender/age (years) Site
MIC (mg/L) (susceptibility category)
PPNG TRNG
23S rRNA mutation
(no. of alleles) NG-MASTazithromycin ceftriaxone ciprofloxacin
1/QLD 2011 male/44 urethra .256 (R) 0.016 (S) 8 (R) yes yes A2059G (4) ST5309
2/NSW 2011 male/39 urethra .256 (R) 0.016 (S) 4 (R) yes yes A2059G (4) ST10572
3/VIC 2013 female/48 vagina .256 (R) 0.016 (S) 8 (R) no yes A2059G (4) ST8917
4/QLD 2013 male/24 urethra .256 (R) ≤0.008 (S) ≤0.03 (S) no no A2059G (4) ST649
5/QLD 2013 male/26 urethra .256 (R) 0.016 (S) ≤0.03 (S) no no A2059G (4) ST649
6/VIC 2013 female/44 cervix .256 (R) 0.016 (S) 8 (R) yes yes A2059G (4) ST10133
NSW, New South Wales; QLD, Queensland; VIC, Victoria; PPNG, penicillinase-producing N. gonorrhoeae; TRNG, tetracycline-resistant N. gonorrhoeae;
S, susceptible; R, resistant.
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